MONTREAL--(BUSINESS WIRE)--April 5, 2006--Gemin X Biotechnologies, Inc. announced today the results of a preclinical study evaluating GX15-070 both as a monotherapy and in combination with the proteasome inhibitor bortezomib (Velcade®) for the treatment of mantle cell lymphoma (MCL). The data demonstrated that GX15-070 induced apoptosis and exhibited synergistic effects with bortezomib. The findings were summarized in a presentation entitled "The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib" (Abstract 2427; Patricia Perez-Galan, et al) during the 97th Annual Meeting of the American Association for Cancer Research (AACR), April 1-5, 2006 in Washington, D.C.
